Dimethyl fumarate for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

Dimethyl fumarate for COVID-19

1 study with >700 patients

Serious outcome risk

Dimethyl fumarate

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Dimethyl fumarate studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−3%

Mortality (1)−3%

RCTs (1)−3%

Late (1)−3%

00.511.5+

← Dimethyl
fumarate
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 2 2025	Horby et al., medRxiv, doi:10.1101/2025.08.29.25334732	Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19
	6-month followup of RECOVERY patients. Results are reported within the respective trials for each treatment.
Jan 31 2024	Horby et al., Nature Communications, doi:10.1038/s41467-023-43644-x	Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
	3% higher mortality (p=0.89), 20% higher ventilation (p=0.65), and 12% worse 7-point scale results (p=0.41). RCT 713 hospitalized COVID-19 patients showing no significant difference in clinical outcomes with dimethyl fumarate. 6-month results are from [Horby]